Health Care Roundup: Market Talk
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
最新的市場會談涉及醫療保健部門。美國東部時間4：20、12：20和16：50在道瓊斯通訊社獨家發佈。
0817 GMT - AstraZeneca PLC's antibody cocktail AZD7442 could help nonhospitalized patients with mild to moderate Covid-19 avoid more severe illness, the drugmaker says in summarized, preliminary trial results. Last week, AstraZeneca asked for U.S. Food and Drug Administration authorization to use the antibody combination for a different purpose, as a preventative shot against symptomatic Covid-19, like a vaccine. Now the company says AZD7442 might also help treat mild to moderate cases in people already infected. Top-line results show it reduced the risk of severe Covid-19 or death by between 50% and 67% if administered within a week after symptoms showed. The company says it's discussing findings with regulators. Full trial results haven't been reviewed by independent researchers or published. (jenny.strasburg@wsj.com)
0817GMT-阿斯利康的抗體雞尾酒AZD7442A可以幫助輕到中度新冠肺炎的非住院患者避免更嚴重的疾病，製藥商在總結的初步試驗結果中説。上週，阿斯利康要求美國食品和藥物管理局(FDA)授權將抗體組合用於不同的目的，作為預防有症狀的新冠肺炎的疫苗，比如疫苗。現在，該公司表示，AZD7442也可能有助於治療已經感染的人中的輕到中度病例。最重要的結果顯示，如果在症狀顯現後一週內使用，它可以將嚴重新冠肺炎或死亡的風險降低50%到67%。該公司表示，正在與監管機構討論調查結果。完整的試驗結果還沒有經過獨立研究人員的審查或發表。(jenny.strasburg@wsj.com)
0625 GMT - Shares of Bayer are expected to trade higher on Monday after Bloomberg reported details about the German chemicals and pharmaceuticals company's planned sale of its pest-control unit, called Environmental Science Professional. The unit is attracting interest from investors such as Bain and Cinven and its price tag would be about EUR2 billion, according to the news outlet. (thomas.leppert@wsj.com)
0625GMT-在彭博社(Bloomberg)報道了這家德國化工和製藥公司計劃出售其名為環境科學專業公司(Environmental Science Professional)的蟲害防治部門的細節後，拜耳的股價週一預計將走高。據新聞媒體報道，該部門正吸引貝恩(Bain)和Cinven等投資者的興趣，其價格約為20億歐元。(thomas.listpert@wsj.com)
0500 GMT - Raffles Medical Group is likely to benefit from the further reopening of Singapore's borders, given it is the sole provider of Covid-19 polymerase chain reaction tests at the country's Changi Airport, RHB Research says. The conversion of the Connect@Changi business facility into a Covid-19 community-care facility should also support near-term revenue growth, the broker says. The likely return of walk-in patients to clinics and inflow of more foreign patients into Singapore could further help, RHB Research says. It keeps a buy call on Raffles Medical and raises the target price to S$1.65 from S$1.45. Shares fall 1.3% to S$1.46. (yongchang.chin@wsj.com)
0500GMT-RHB Research表示，鑑於萊佛士醫療集團是新加坡樟宜機場新冠肺炎聚合酶鏈式反應檢測的唯一提供商，該集團可能會從新加坡邊境的進一步開放中受益。該經紀商表示，將Connect@Changi商業設施轉變為新冠肺炎社區護理設施，也應該會支持近期的收入增長。RHB Research説，無預約患者可能會回到診所，更多的外國患者湧入新加坡，這可能會進一步幫助患者。它繼續買入萊佛士醫療公司(Raffles Medical)的股票，並將目標價從1.45新元上調至1.65新元。股價下跌1.3%，至1.46新元。(yongchang.chin@wsj.com)
0333 GMT - Hartalega Holdings' strong earnings performance for FY 2022 is unlikely to be sustainable, as average selling prices have been trending downward since May on rising competition, especially in the nitrile glove segment, says Maybank IB Research. It says China is a threat that cannot be ignored, as Chinese glove makers' aggressive capacity expansion likely led to oversupply by 2023. Maybank reduces forecasts for the glove maker's earnings by 1%-62% for FY 2022-2024 after lowering plant utilization rate and average selling prices assumptions. Maybank downgrades its rating on the stock from hold to sell and cuts its target price from MYR6.74 to MYR3.99. Shares are 1.4% lower at MYR5.81. (chester.tay@wsj.com)
033GMT-Maybank IB Research表示，Hartalega Holdings在2022財年的強勁收益表現不太可能持續，因為由於競爭加劇，平均售價自5月份以來一直在下降，特別是在丁腈手套領域。報告稱，中國是一個不容忽視的威脅，因為中國手套製造商積極的產能擴張可能導致2023年供應過剩。Maybank在下調工廠利用率和平均售價假設後，將這家手套製造商2022-2024財年的收益預期下調了1%-62%。Maybank將該股評級從持有下調至賣出，目標價從6.74馬幣下調至3.99馬幣。股價下跌1.4%，至5.81馬幣。(chester.tay@wsj.com)
譯文內容由第三人軟體翻譯。